What could a tree possibly reveal about the European Society for Medical Oncology (ESMO)? Quite a lot, says Prof Andres Cervantes, Professor of Medicine at the University of Valencia, Spain ...

Regeneron Pharmaceuticals’ investigational melanoma combination therapy shows continued response after two years in a Phase I ...

Targeted therapy has seen a threefold increase in the 12-month progression free survival (PFS) rate versus standard of care ...

The following abstracts showcase the top cutting-edge research presented at the European Society for Medical Oncology (ESMO) ...

Susanne Bobadilla from VML Health, joined by a team of 15 medical, digital strategists and client engagement experts from across the company, looks at the top trends coming out of ESMO 2024 and what ...

Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

Shares of Sutro Biopharma (NASDAQ:STRO) fell by 17% in September after the company's ESMO (European Society for Medical Oncology) update. 3-year performance isn't looking much better at -81% ...

The results were published through poster presentation at the 2024 European Society for Medical Oncology (ESMO 2024). This Phase I, open-label, dose-escalation and expansion study was conducted ...

esmo group has launched its latest product—the Apollo Quad Handler. Designed to bridge the gap between the engineering and ...

Personalis, Inc. (Nasdaq: PSNL), a leader in MRD testing, announced findings presented this week at the European Society of Medical Oncology Congress (ESMO) Congress 2024 in Barcelona, Spain.

Abstracts will be made available on the ESMO I-O website on 5 December 2024 at 00:05 CET. The poster containing new data, not in the abstract, will be available on the Posters & Publications section ...